A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects.
Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.
Conditions: Intracranial Tumors
Interventions: Device: ExAblate 4000 System
Eligibility: 8 Years to 22 Years
Principal Investigator: John Ragheb
Learn more at https://clinicaltrials.gov/study/NCT03028246.
Predicting Seizure Responsiveness to Neuromodulation Using Connectomic Profiling (Vagus Nerve Stimulation [VNS] Study)
Conditions: Epilepsy
Principal Investigator: Shelly Wang
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995963/.
A Phase 2 dose-escalation study examining the safety, pharmacokinetics, and preliminary efficacy of ascending drug and energy dose combinations for sonodynamic therapy using SONALA-001 in combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in subjects with Diffuse Intrinsic Pontine Glioma (DIPG)
Conditions: Glioma
Principal Investigator: Toba Niazi
Learn more at https://clinicaltrials.gov/study/NCT05123534.
A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)
Conditions: Diffuse Intrinsic Pontine Gliomas
Principal Investigator: Toba Niazi
Learn more at https://clinicaltrials.gov/study/NCT05630209.